SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations in BRCA1/2 and other DNA repair pathway genes....

Full description

Bibliographic Details
Main Authors:	Lu, Z, Mao, W, Yang, H, Santiago-O'Farrill, JM, Rask, PJ, Mondal, J, Chen, H, Ivan, C, Liu, X, Liu, C-G, Xi, Y, Masuda, K, Carrami, EM, Chen, M, Tang, Y, Pang, L, Lakomy, DS, Calin, GA, Liang, H, Ahmed, AA, Vankayalapati, H, Bast, RC
Format:	Journal article
Language:	English
Published:	American Society for Clinical Investigation 2022

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

Similar Items